Q3 2026 Gufic Biosciences Ltd Earnings Call Transcript
Key Points
- Gufic Biosciences Ltd (BOM:509079) reported a stable turnover for Q3 FY26 at INR231.1 crores, showing resilience in a challenging market.
- The company has made significant progress in its international business, with regulatory approvals in Germany, Portugal, and Lithuania, and expanded registrations in Myanmar.
- The women's health platform has shown growth, with core brands like Dufusin Alpha and Puregraf performing well.
- The company is focusing on high-value segments such as critical care and women's health, which are expected to drive future growth.
- Gufic Biosciences Ltd (BOM:509079) is expanding its capacity utilization at the indoor facility, which is expected to improve margins in the future.
- The company's EBITDA margin slightly decreased from 16.45% in Q2 to 16.05% in Q3 FY26.
- There has been a significant hit on working capital due to a strategic shift in hospital supply operations, impacting cash flow.
- The domestic business growth was limited to around 8% due to challenges in the critical care and SPARSH divisions.
- Employee benefit expenses have been rising, impacting overall profitability.
- The company is facing challenges in achieving higher growth rates due to regulatory and operational hurdles, with a cautious outlook for FY27.
Ladies and gentlemen, good day and welcome to the Gufic Biosciences Limited Q3 FY26 earnings conference call.
(Operator Instructions)
Please note that this conference is being recorded.
I now hand the conference over to Ms. Shweta Shetty, Assistant Company Secretary at Gufic Biosciences Limited.
Thank you. Hand over to you, ma'am.
Good afternoon, everyone. I welcome you all to Gufic Biosciences Ltd Earnings Conference call for the third quarter of financial year FY26. We have with us today for the call Mr. Pranav J. Choksi, CEO and full-time Director, Mr. Devkinandan B. Roonghta, CFO, and Mr. Avik Das from Investor Relations team to give the highlights of the business and financial performance of the company and to take questions, if any.
Before we begin, I would like to say that some of the statements that will be made in today's discussion may include certain forward-looking statements which are projections or estimates about future events.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
